公开(公告)号：US07945263B2

公开(公告)日：2011-05-17

申请号：US11288712

申请日：2005-11-29

申请人： John Noll ,  Jeffrey W. Smith ,  Mark Nelson ,  John F. Schwaller

发明人： John Noll ,  Jeffrey W. Smith ,  Mark Nelson ,  John F. Schwaller

IPC分类号： H04Q7/20

CPC分类号： H04W36/0055 ,  H04W16/28

摘要： Method for transferring service for a mobile station call signal from a first base transceiver station to a second base transceiver station in a wireless mobile telecommunication system, while a call is in progress. The method can include receiving at a base transceiver station an access burst from a mobile station with a call already in progress and requiring service from the base transceiver station. Based on the received access burst, the base transceiver station can electronically steer a beam of an adaptive antenna array of the base transceiver station toward a location of the mobile station.

摘要翻译： 当呼叫正在进行时，用于将移动台呼叫信号的服务从无线移动电信系统中的第一基站收发台转移到第二基站收发台的方法。 该方法可以包括在基站收发台处接收来自具有呼叫的移动台的接入脉冲串，并且需要来自基站的服务。 基于所接收的接入脉冲串，基站收发台可以将基站收发信站的自适应天线阵列的波束电子地转向移动台的位置。

公开(公告)号：US20100173982A1

公开(公告)日：2010-07-08

申请号：US12620412

申请日：2009-11-17

申请人： Jeffrey W. Smith ,  Fumiko Axelrod ,  Steven J. Kridel ,  Daniel Romo ,  Vikram Purohit ,  Gil Ma

发明人： Jeffrey W. Smith ,  Fumiko Axelrod ,  Steven J. Kridel ,  Daniel Romo ,  Vikram Purohit ,  Gil Ma

IPC分类号： A61K31/335 ,  C07D305/12

CPC分类号： A61K31/336 ,  A61K31/335 ,  A61K31/337 ,  A61K31/365 ,  A61K31/40 ,  A61K31/42 ,  A61K31/425 ,  A61K31/445 ,  A61K31/585 ,  G01N33/5011 ,  G01N2333/91057

摘要： The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis. The invention also features methods of synthesizing beta-lactones and features novel beta-lactone compounds.

摘要翻译： 本发明的特征在于通过向受试者施用有效量的β-内酯来治疗受试者的癌症的方法。 本发明还具有通过向受试者施用有效量的脂肪酸合酶抑制剂来抑制受试者血管生成的方法。 这些方法可用于治疗各种癌症和其他疾病和病症。 本发明还涉及鉴定可用于本发明治疗肿瘤，抑制血管发生以及涉及病理性血管生成的疾病和病症的治疗的β-内酯和其它化合物的方法。 本发明还具有合成β-内酯并具有新型β-内酯化合物特征的方法。

公开(公告)号：US20090124681A1

公开(公告)日：2009-05-14

申请号：US12262101

申请日：2008-10-30

申请人： Jeffrey W. Smith ,  Daniel Romo ,  Gil Ma ,  Manuel Zancanella

发明人： Jeffrey W. Smith ,  Daniel Romo ,  Gil Ma ,  Manuel Zancanella

IPC分类号： A61K31/4164 ,  C07D305/12 ,  A61K31/337 ,  A61P29/00 ,  A61P31/00 ,  A61P37/00 ,  A61P35/00 ,  C07D233/54

CPC分类号： C07D305/12

摘要： The present invention provides compounds having the general structure A, or a pharmaceutically acceptable derivatives thereof: wherein R is an alkyl group, and R1 comprises at least one moiety selected from a group consisting of an alkyl, an alkenyl, an aryl, a heterocycle, hydroxyl, ester, amido, aldehyde, and a halogen.

摘要翻译： 本发明提供具有通式结构A的化合物或其药学上可接受的衍生物：其中R是烷基，R 1包含至少一个选自烷基，烯基，芳基，杂环， 羟基，酯，酰氨基，醛和卤素。

公开(公告)号：US06184206B2

公开(公告)日：2001-02-06

申请号：US09146503

申请日：1998-09-02

申请人： Jeffrey W. Smith ,  Dana D. Hu

发明人： Jeffrey W. Smith ,  Dana D. Hu

IPC分类号： A61K3800

CPC分类号： C07K16/2848 ,  A61K38/08 ,  A61K38/363 ,  C07K14/75

摘要： The invention provides a method of disaggregating a ligand:integrin receptor complex. Specifically, the invention provides a method of disaggregating an existing platelet thrombus in a blood vessel in a subject, comprising administering to the subject a compound which dissociates fibrinogen bound to a first site on platelet glycoprotein IIB-IIIa, by binding a second interacting site on the platelet glycoprotein IIB-IIIa, thereby disaggregating the platelet thrombus. The present invention also provides a method of screening compounds for the ability to dissociate a ligand from its integrin receptor by binding an interacting second site, comprising contacting the compound with an existing ligand:integrin receptor complex and determining if the complex dissociates.

摘要翻译： 本发明提供了分解配体：整联蛋白受体复合物的方法。 具体地说，本发明提供了一种分解受试者血管中的现有血小板血栓的方法，其包括通过将第二相互作用位点结合到受试者上来解离与血小板糖蛋白IIB-IIIa上的第一部位结合的纤维蛋白原的化合物 血小板糖蛋白IIB-IIIa，从而分解血小板血栓。 本发明还提供了一种筛选化合物以通过结合相互作用的第二位点将配体从其整联蛋白受体解离的能力的方法，包括使化合物与现有的配体：整联蛋白受体复合物接触并确定复合物是否解离。

公开(公告)号：US5611910A

公开(公告)日：1997-03-18

申请号：US599773

申请日：1996-02-12

申请人： Jorge A. Marzari ,  Michael R. Franzen ,  Jeffrey W. Smith

发明人： Jorge A. Marzari ,  Michael R. Franzen ,  Jeffrey W. Smith

IPC分类号： B01D53/50 ,  C10C3/02 ,  C10C3/04 ,  C10C1/20

CPC分类号： C10C3/04 ,  B01D53/501 ,  B01D53/507 ,  C10C3/023

摘要： In a method for reducing emissions from an asphalt blowing process, an emission reducing additive is added to the asphalt prior to blowing, or early in the blowing process. The emission reducing additive is added in an amount sufficient to reduce the SO.sub.x emissions from the blowing process by at least 25 percent by weight when compared with the same process without the emission reducing additive. The emission reducing additive includes at least two compounds selected from metal hydroxides, metal oxides, metal carbonates and metal bicarbonates, where the metal is selected from sodium, potassium, calcium, magnesium, zinc, copper and aluminum.

摘要翻译： 在减少沥青吹制过程的排放的方法中，在吹制之前或在吹制过程的早期，将沥青添加到沥青中。 当与不含减排添加剂的相同方法相比时，减少排放添加剂的量足以将来自吹制过程的SO x排放量减少至少25重量％。 减排添加剂包括选自金属氢氧化物，金属氧化物，金属碳酸盐和金属碳酸氢盐中的至少两种化合物，其中金属选自钠，钾，钙，镁，锌，铜和铝。

公开(公告)号：US20130171208A1

公开(公告)日：2013-07-04

申请号：US13779022

申请日：2013-02-27

申请人： Jeffrey W. Smith

发明人： Jeffrey W. Smith ,  Hui Xie

IPC分类号： A61K47/30

CPC分类号： A61K47/30 ,  A61K9/5153 ,  A61K9/5192 ,  A61K31/00 ,  A61K31/337 ,  A61K31/704 ,  A61K45/06 ,  A61K47/34 ,  B01F3/0807 ,  B01F5/0471 ,  B01F5/0475 ,  B01F5/048 ,  B01F13/0059 ,  B82Y5/00 ,  A61K2300/00

摘要： Disclosed herein are compositions of nanoparticles. In some embodiments, the nanoparticles are Janus particles, where each particle includes a first component and second component that are exposed to the surface of the particle. Also, disclosed are methods and systems for making a composition of nanoparticles. Finally, a method of treating a mammal by administering a composition of nanoparticles is disclosed.

摘要翻译： 本文公开了纳米颗粒的组合物。 在一些实施方案中，纳米颗粒是Janus颗粒，其中每个颗粒包括暴露于颗粒表面的第一组分和第二组分。 此外，公开了制备纳米颗粒组合物的方法和系统。 最后，公开了一种通过施用纳米颗粒组合物治疗哺乳动物的方法。

公开(公告)号：US08124794B2

公开(公告)日：2012-02-28

申请号：US12620412

申请日：2009-11-17

申请人： Jeffrey W. Smith ,  Fumiko Axelrod ,  Steven J. Kridel ,  Daniel Romo ,  Vikram Purohit ,  Gil Ma

发明人： Jeffrey W. Smith ,  Fumiko Axelrod ,  Steven J. Kridel ,  Daniel Romo ,  Vikram Purohit ,  Gil Ma

IPC分类号： C07D305/00

CPC分类号： A61K31/336 ,  A61K31/335 ,  A61K31/337 ,  A61K31/365 ,  A61K31/40 ,  A61K31/42 ,  A61K31/425 ,  A61K31/445 ,  A61K31/585 ,  G01N33/5011 ,  G01N2333/91057

摘要： The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis. The invention also features methods of synthesizing beta-lactones and features novel beta-lactone compounds.

摘要翻译： 本发明的特征在于通过向受试者施用有效量的β-内酯来治疗受试者的癌症的方法。 本发明还具有通过向受试者施用有效量的脂肪酸合酶抑制剂来抑制受试者血管生成的方法。 这些方法可用于治疗各种癌症和其他疾病和病症。 本发明还涉及鉴定可用于本发明治疗肿瘤，抑制血管发生以及涉及病理性血管生成的疾病和病症的治疗的β-内酯和其它化合物的方法。 本发明还具有合成β-内酯并具有新型β-内酯化合物特征的方法。

公开(公告)号：US20110200996A1

公开(公告)日：2011-08-18

申请号：US12959349

申请日：2010-12-02

申请人： Jeffrey W. Smith ,  Changming FANG

发明人： Jeffrey W. Smith ,  Changming FANG

IPC分类号： C12Q1/68 ,  G01N33/53 ,  G01N33/566 ,  G01N33/577

CPC分类号： C12Q1/6886 ,  C12Q2600/106

摘要： We have identified a new variant of ileal bile acid binding protein (IBABP), designated IBABP-L, which is a biomarker for colorectal cancer. The transcript for IBABP-L arises from an alternative start site and includes three exons that are absent in IBABP. IBABP-L also shares part of a fourth exon with IBABP. The protein encoded by IBABP-L contains a deduced 49 residue N-terminal sequence that is not found in the IBABP protein. The present invention provides methods for diagnosing colorectal cancer and other compositions and methods based on this discovery.

摘要翻译： 我们已经确定了回肠胆汁酸结合蛋白（IBABP）的新变体，称为IBABP-L，其是结肠直肠癌的生物标志物。 IBABP-L的成绩单来自替代起始位点，并且包括IBABP中缺少的三个外显子。 IBABP-L还与IBABP共享第四外显子的一部分。 由IBABP-L编码的蛋白质包含在IBABP蛋白中未发现的49个残基的N-末端序列。 本发明提供了用于诊断结肠直肠癌的方法以及基于该发现的其它组合物和方法。

公开(公告)号：US20100305121A1

公开(公告)日：2010-12-02

申请号：US12778944

申请日：2010-05-12

申请人： Jeffrey W. Smith ,  Robyn D. Richardson

发明人： Jeffrey W. Smith ,  Robyn D. Richardson

IPC分类号： A61K31/515 ,  C07D405/06 ,  C07D413/06 ,  A61K31/5377 ,  C12N5/00 ,  G01N33/68 ,  A61P35/00 ,  A61P3/04 ,  A61P19/02 ,  A61P17/06

CPC分类号： C07D405/06 ,  C07D239/62 ,  C07D239/74 ,  C07D471/04

摘要： The present invention provides for compounds of formula (I)-(XIII), as well as pharmaceutically acceptable salts thereof, metabolites thereof, pro-drugs thereof, and pharmaceutical kits that include such compounds. The present invention also provides for the compounds of formula (I)-(XIII) for use in medical therapy or diagnosis. The present invention also provides for the use of the compounds of formula (I)-(XIII) in treating cancer in mammals (e.g., humans), as well inhibiting tumor cell growth in such mammals. The present invention also provides for methods of inhibiting FAS. The methods include contacting FAS with an effective amount of a compound of formula (I)-(XIII). The present invention also provides for methods of inhibiting the TE domain of the FAS. The methods include contacting the thioesterase TE domain of the FAS with an effective amount of a compound of formula (I)-(XIII). The present invention also provides for methods of treating cancer in mammals, as well as methods of inhibiting tumor cell growth in such mammals. The methods include administering a compound of formula (I)-(XIII) to a mammal in need of such treatment.

摘要翻译： 本发明提供式（I） - （XIII）化合物及其药学上可接受的盐，其代谢物，其前药和包括这些化合物的药物试剂盒。 本发明还提供用于药物治疗或诊断的式（I） - （XIII）化合物。 本发明还提供式（I） - （XIII）化合物在哺乳动物（例如人）中治疗癌症中的用途，以及抑制这些哺乳动物的肿瘤细胞生长。 本发明还提供了抑制FAS的方法。 所述方法包括使FAS与有效量的式（I） - （XIII）化合物接触。 本发明还提供了抑制FAS的TE结构域的方法。 所述方法包括使FAS的硫酯酶TE结构域与有效量的式（I） - （XIII）化合物接触。 本发明还提供了治疗哺乳动物癌症的方法，以及抑制这些哺乳动物肿瘤细胞生长的方法。 所述方法包括向需要这种治疗的哺乳动物施用式（I） - （XIII）化合物。

公开(公告)号：US20100057268A1

公开(公告)日：2010-03-04

申请号：US12200992

申请日：2008-08-29

申请人： Jeffrey W. Smith ,  Kyung Soo Kook

发明人： Jeffrey W. Smith ,  Kyung Soo Kook

IPC分类号： G05B17/02 ,  G06F17/10

CPC分类号： H01G9/155 ,  H02J3/28 ,  H02J2003/007 ,  Y02E60/13 ,  Y02E60/76 ,  Y04S40/22

摘要： A method and model for evaluating transmission ultracapacitor response in a power system. The method includes the steps of implementing a transmission ultracapacitor model into power system simulation software, simulating a desired condition of a power system, and determining a desired output power of a transmission ultracapacitor to define a control setpoint. The method further includes the steps of determining the transmission ultracapacitor limit, such that the desired output power does not exceed the transmission ultracapacitor limit, responding to the condition by adjusting output according to the control setpoint, and using the output in conjunction with other elements in the power system to determine an overall system response.

摘要翻译： 用于评估电力系统中传输超级电容器响应的方法和模型。 该方法包括以下步骤：将传输超级电容器模型实现到电力系统仿真软件中，模拟电力系统的期望状态，以及确定传输超级电容器的期望输出功率以定义控制设定点。 该方法还包括以下步骤：确定传输超级电容器限制，使得期望的输出功率不超过传输超级电容器极限，通过根据控制设定点调节输出来响应该条件，并将输出与其他元件结合使用 电力系统确定整体系统响应。